This Is What Executives From Major Companies Said About Tariffs This Week (Part 1)
$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck Gains After Latest Survival Data for Summit's Cancer Drug
What's Going On With Summit Therapeutics Stock On Friday?
Eli Lilly Seeks a Review of EU Rejection of Alzheimer's Therapy
SA Analyst Downgrades: T, DOW, SMCI, UNH
Summit Plunges 35%; Partner Akesso Wins FDA Nod for Cancer Drug
About 75% of the Names That Reported Earnings This Week Delivered EPS Wins: Earnings Scorecard
Earnings Call Summary | AbbVie(ABBV.US) Q1 2025 Earnings Conference
'Akeso Wins Chinese Approval For Cancer Drug Positioned To Rival Merck's Keytruda; Company Discloses Early Data Hinting At A Survival Benefit' - STAT News
Check Out What Whales Are Doing With UNH
ALX Oncology Falls on Mid-stage Trial Setback for Lead Asset
UnitedHealth Group Shares Are Trading Lower After Barclays Cut Its Price Target on the Stock From $560 to $513.
Pharma Tariffs Could Raise Prescription Drug Costs by $51B - Report
4 Stocks to Watch on Friday: GILD, ABBV, CL and SLB
AbbVie Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Adjusted EPS Guidance.
Earnings Snapshot: AbbVie Tops Q1 Estimates Even as Humira Sales Lag, Profit Outlook Beats
AbbVie Non-GAAP EPS of $2.46 Beats by $0.06, Revenue of $13.34B Beats by $420M
Ozempic Compounders Suffer Fresh Setback as Judge Rejects Injunction